Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
envafolimab + lenvatinib + FOLFOX-HAIC
- Development stage
- Unknown
- Lead developer
- 3D Medicines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Oral, Intra-arterial, Intravenous
01
Overview
This combination therapy regimen is being investigated as a conversion therapy for patients with potentially resectable hepatocellular carcinoma (HCC). It consists of **envafolimab** (also referred to as envolizumab), a recombinant humanized single-domain antibody (nanobody) that acts as a PD-L1 inhibitor; **lenvatinib**, an oral multi-kinase inhibitor targeting VEGFR, FGFR, and other receptor tyrosine kinases; and **FOLFOX-HAIC**, which involves Hepatic Arterial Infusion Chemotherapy (HAIC) using the FOLFOX regimen (oxaliplatin, leucovorin, and 5-fluorouracil). The strategy combines localized high-dose chemotherapy delivered directly to the liver with systemic anti-angiogenic and immunotherapy to downstage tumors and improve the feasibility of surgical resection.
- Brand names
- EnweidaLenvima
- Other names
- envolizumab + lenvatinib + FOLFOX-HAICFOLFOX-HAIC + lenvatinib + envolizumabFOLFOX-HAIC + lenvatinib + envafolimabenvafolimab + lenvatinib + oxaliplatin + leucovorin + 5-fluorouracil
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR-1 (Vascular endothelial growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)DNAFGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on envafolimab + lenvatinib + FOLFOX-HAIC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on envafolimab + lenvatinib + FOLFOX-HAIC.